Prosecution Insights
Last updated: November 04, 2026
Application No. 18/748,428

WOUND DRESSING, WOUND GEL AND COSMETIC

Final Rejection §102
Filed
Jun 20, 2024
Priority
Dec 23, 2021 — DE 10 2021 215 013.6 +1 more
Examiner
ALLEY, GENEVIEVE S
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Polymedics Innovations GmbH
OA Round
2 (Final)
61%
Grant Probability
Moderate
3-4
OA Rounds
6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
451 granted / 743 resolved
+0.7% vs TC avg
Strong +48% interview lift
Without
With
+48.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
30 currently pending
Career history
784
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
50.0%
+10.0% vs TC avg
§102
14.1%
-25.9% vs TC avg
§112
18.9%
-21.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 743 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims A new claim set was filed on 8/10/26 with the following: Amended claims 1, 12-17 Newly canceled claims Newly added claims Previously canceled claims 20 Previously withdrawn claims 19, 22 Claims under instant examination 1-18, 21 Withdrawn Claim Rejections The rejections of claims 1-19 and 21-22 under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention are hereby withdrawn in view of the claim amendments filed on 8/10/26. The rejections of: claims 1-5 and 17-18 under 35 U.S.C. 102(a)(1) as being anticipated by Hierlemann et al. (US 2002/0028231; published: 3/7/02; thereafter referred to as Hierlemann A) are hereby withdrawn in view of the persuasive arguments presented by Applicants on 8/10/26. Maintained Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-18 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Hierlemann et al. (WO 2015/189389; published: 6/12/15; thereafter referred to as Hierlemann B; of record). The English language machine translation of WO 2015/189389 was previously provided. The passages cited below which indicate the teachings of the ‘389 publication are based on its English translation. Hierlemann B is directed to wound contact material for use in the treatment and/or care of wounds [Title]. With regards to instant claims 1-5, Hierlemann B teaches a wound contact material comprising a terpolymer composed of lactic acid, trimethylene carbonate and ε-caprolactone units, wherein the material has a porosity > 80%, a pore size of 0.1-800 µm (e.g., 0.5-30 µm), a particle size ranging from 0.1 to 1000 µm (e.g., 10-350 µm) [claims, description]. With regards to instant claims 15-1[[5]]6, Hierlemann B teaches wherein the wound contact material contains a polymer blend; wherein the polymer blend comprises the abovementioned polymer in combination with another polymer such as polyvinyl alcohol [description]. With regards to instant claim 17, Hierlemann B teaches wherein the wound contact material is membrane-shaped (e.g., in the form of a solidified membrane), foam-shaped or film-shaped [description]. With regards to instant claim 18, Hierlemann B teaches wherein the wound contact material assumes a gelatinous or gel-like consistency [description]. With regards to instant claims 6-14, the MPEP states the following (MPEP §2112(I)): I. SOMETHING WHICH IS OLD DOES NOT BECOME PATENTABLE UPON THE DISCOVERY OF A NEW PROPERTY “[T]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art' s functioning, does not render the old composition patentably new to the discoverer.” Atlas Powder Co. v. Ireco Inc., 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. In re Best, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977). In the instant case, Hierlemann B teaches the wound agent of instant claim 1; more specifically, Hierlemann B teaches the same terpolymer as claimed and wherein such terpolymer is made in the same general way. Therefore, in view of MPEP §2112, claiming a new use/function/property for such known composition (e.g., bulk density, volume weight, bimodal pore structure, %wt of free monomers), which is inherently present in the prior art, does not necessarily make the claim patentable. Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). “When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not.” In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Therefore, the prima facie case can be rebutted by evidence showing that the prior art products do not necessarily possess the characteristics of the claimed product. In re Best, 562 F.2d at 1255, 195 USPQ at 433. Therefore, by teaching all the limitations of claims 1-18, Hierlemann B anticipates the instant invention as claimed. Response to Arguments Applicants’ arguments with regard to the previously cited prior art are moot in view of the withdrawn claim rejections. To the extent that Applicants’ arguments are pertinent to the newly applied rejections, they are addressed as follows: Applicants argue that although Hierlemann B separately descripbes the recited terpolymer, particulate would-contact material, and wound-contact material having porosity greater than 80%, Hierlemann B does not state that the disclosed powder or flakes are themselves porous or that each such particle has porosity greater than 80% [Remarks: p. 6]. This is not found persuasive. In response, and as indicated in the rejection, Hierlemann B teaches “a wound contact material comprising a terpolymer composed of lactic acid, trimethylene carbonate and ε-caprolactone units, wherein the material has a porosity > 80%, a pore size of 0.1-800 µm (e.g., 0.5-30 µm), a particle size ranging from 0.1 to 1000 µm (e.g., 10-350 µm) [claims, description].” The above summary of the teachings of Hierlemann come from the following statements in the description: “In a further embodiment, the wound contact material has a porosity of > 80%, in particular of 80% to 96%, preferably 85% to 96%, more preferably 90% to 96%.” “In a further embodiment, the wound contact material is present in particulate form, in particular in the form of a powder (finely ground, generally dry solid), powder (particle size fine to coarse) or in the form of flakes (flakes, flakes or leaflets).” “Such a wound contact material can have a particle size, in particular grain size, of 0.1 μm to 1000 μm, in particular 1 μm to 500 μm, preferably 10 μm to 350 μm.” It is true that Hierlemann does not disclose in one sentence that the wound contact material is in particle form AND that that particle wound contact material has porosity of > 80%. However, Hierlemann B only teaches 2 possible forms of the wound contact material: 1) planar structure (e.g., membrane or film) or 2) particulate form (e.g., powder or flakes). Even within these two possible forms, Hierlemann B only teaches 7 types: films, membranes, foams, meshes, nonwovens, powders and flakes, as mentioned by Applicants [Remarks: p. 7]. An anticipation rejection over the abovementioned limitation over Hierlemann is supported by MPEP 2131.02, which states: A reference disclosure can anticipate a claim even if the reference does not describe "the limitations arranged or combined as in the claim, if a person of skill in the art, reading the reference, would ‘at once envisage’ the claimed arrangement or combination." Such is especially true in the instant case, where there is not a teaching away and the generic disclosure includes two possible forms of the wound contact material (one of which is particulate form), wherein the generic wound contact material has a porosity > 80%. Attention is directed to MPEP §2131.02 (III), which states: “If one of ordinary skill in the art is able to "at once envisage" the specific compound within the generic chemical formula, the compound is anticipated. One of ordinary skill in the art must be able to draw the structural formula or write the name of each of the compounds included in the generic formula before any of the compounds can be "at once envisaged." One may look to the preferred embodiments to determine which compounds can be anticipated. In re Petering, 301 F.2d 676, 133 USPQ 275 (CCPA 1962).” Applicants argue that contrary to the cited prior art, the production of porous particles according to Applicant’s invention requires several steps as taught in [0055-0065] [Remarks: p. 7]. In response to applicant's argument that the references fail to show certain features of the invention, it is noted that the features upon which applicant relies (i.e., method steps) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GENEVIEVE S ALLEY whose telephone number is (571)270-1111. The examiner can normally be reached Monday-Friday 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Blanchard can be reached at 571-272-0827. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GENEVIEVE S ALLEY/ Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Jun 20, 2024
Application Filed
May 19, 2026
Non-Final Rejection mailed — §102
Aug 10, 2026
Response Filed
Oct 19, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778131
ANTIMICROBIAL GLASS COMPOSITIONS, GLASSES AND POLYMERIC ARTICLES INCORPORATING THE SAME
4y 2m to grant Granted Nov 03, 2026
Patent 12781317
MODIFIED CAST METAL OBJECT
2y 11m to grant Granted Nov 03, 2026
Patent 12779092
HYALURONIC ACID-BASED HYDROGEL PRECURSOR SOLUTION, HYALURONIC ACID-BASED HYDROGEL AND REPAIR MATERIAL THEREOF
2y 8m to grant Granted Nov 03, 2026
Patent 12767970
METHODS AND COMPOSITIONS FOR MELANIN SYNTHESIS
3y 4m to grant Granted Oct 20, 2026
Patent 12760304
STABILIZATION OF RNA FOR EXOGENOUS RNAi AGRICULTURAL APPLICATIONS AND FORMULATIONS
4y 5m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
61%
Grant Probability
99%
With Interview (+48.0%)
2y 11m (~6m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 743 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month